Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)
The purpose of this study is to describe the real-life use of Cabometyx® in monotherapy or in combination with nivolumab in Belgium in patients with advanced or metastatic Renal Cell Carcinoma (1st, 2nd and later lines of treatment)
Advanced or Metastatic Renal Cell Carcinoma
Treatment line, Treatment line will be assessed at baseline. It is a percentage of patients receiving cabozantinib as 1st, 2nd or later lines of treatment or cabozantinib in monotherapy or in combination with nivolumab as 1st line of treatment., Baseline|Dose reductions and reasons, Number of dose reductions and reason, From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop|Treatment interruptions and reason, Number of treatment interruptions and reason, From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop|Treatment discontinuations and reason, Number of patients with permanent discontinuation and reason, From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop|Alternative dose schedule, Number of patients with schedules other than 1 pill at fixed dose/day for the total treatment period, From baseline until the end of study up to 9 months|Mean number of any dose modification, From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop|Median number of any dose modification, From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop|Median time to any first dose modification, From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop|Median time to end of treatment, From baseline until the end of study up to 9 months|Duration of treatment exposure, From baseline until the end of study up to 9 months|Dose prescribed at initiation, Number of patients with dose of 60 mg/day, 40 mg/day or 20 mg/day at baseline, Baseline|Average daily dose, Estimation of average daily dose received by subject during the treatment exposure, From baseline until the end of study up to 9 months
Change in Quality of Life score, Changes in quality of life data by comparing changes in scores on Using the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Symptom Index-19 (NFKSI-19). It describes the severity, interference, and frequency rates., From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop|Progression Free Survival (PFS), Radiological progression using RECIST 1.1 or investigator assessed or according to local standard of care or death; PFS evaluated at least every 12 weeks under treatment with cabozantinib, From baseline until the end of study up to 9 months|Objective Response Rate, Percent of patients with partial and complete response during the treatment with cabozantinib, From baseline until the end of study up to 9 months|Disease Control Rate, Percent of patients with stable disease, partial and complete response during the treatment with cabozantinib, From baseline until the end of study up to 9 months
The purpose of this study is to describe the real-life use of Cabometyx® in monotherapy or in combination with nivolumab in Belgium in patients with advanced or metastatic Renal Cell Carcinoma (1st, 2nd and later lines of treatment)